Condition
Alpha1-Antitrypsin Deficiency clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Alpha1-Antitrypsin Deficiency clinical trials that are recruiting, at sites in 19 countries (most in Austria (3), Germany (3), Spain (3)). By phase: Phase 3 (2), Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 19Countries
Newest Alpha1-Antitrypsin Deficiency clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Testing CE1226 doses to slow lung disease in adults with alpha-1 antitrypsin deficiency | Phase 4 | Aalborg and 1 other locations | Recruiting | Jan 8, 2026 |
| Understanding liver problems in adults with Alpha-1 Antitrypsin Deficiency | — | Gainesville, Florida and 7 other locations | Recruiting | Jul 22, 2024 |
| Investigating the safety and effects of Fazirsiran for liver disease caused by Alpha-1 Antitrypsin Deficiency | Phase 3 | Phoenix, Arizona and 40 other locations | Recruiting | Dec 11, 2023 |
| Evaluating the safety and effectiveness of fazirsiran for liver disease caused by an abnormal protein. | Phase 3 | Birmingham, Alabama and 88 other locations | Recruiting | Jan 10, 2023 |
All recruiting trials (4)
-
Testing CE1226 doses to slow lung disease in adults with alpha-1 antitrypsin deficiency
This trial tests two active doses of CE1226 to see if they slow lung density decline in adults with AAT deficiency and emphysema over 3 years compared with the standard 60 mg/kg dose.
-
Understanding liver problems in adults with Alpha-1 Antitrypsin Deficiency
This study looks at how liver problems develop over time in adults with Alpha-1 Antitrypsin Deficiency to better understand their health and improve treatment options.
-
Investigating the safety and effects of Fazirsiran for liver disease caused by Alpha-1 Antitrypsin Deficiency
This study is testing a new medication called Fazirsiran to see if it can safely help people with liver disease caused by Alpha-1 Antitrypsin Deficiency by reducing a harmful protein.
-
Evaluating the safety and effectiveness of fazirsiran for liver disease caused by an abnormal protein.
This study is testing if a new drug called fazirsiran can help reduce liver scarring in people with Alpha-1 Antitrypsin Deficiency.
Related topics
Quick answers
How many Alpha1-Antitrypsin Deficiency clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 19 countries. The most sites are in Austria (3 trials), Germany (3 trials), Spain (3 trials), United Kingdom (3 trials), United States (3 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.